STTK stock forecast, quote, news & analysis
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases... Show more
STTK Stock The volume for Shattuck Labs stock increased for one day, resulting in a record-breaking daily growth of 384% of the 65-Day Volume Moving Average
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering novel therapies for autoimmune and inflammatory diseases, is exhibiting signs of a strong uptrend fueled by a dramatic surge in trading volume. This one-day volume growth resulted in a record-breaking increase of 384%, as compared to the 65-Day Volume Moving Average. STTK's total volume now sits at 1.8M. The +2.37% price change was insignificant, leaving STTK's price at $4.75. This volume move could indicate a change in trend, and may be a buy signal for investors. A.I.dvisor found 13 similar cases, 13 of which were successful. Based on this data, the odds of success are +90%. This momentum aligns with STTK's impressive performance, having rallied approximately 286% throughout 2025, outperforming the broader market and reflecting investor confidence in its innovative pipeline amid advancements in clinical development.
Key Takeaways
- Record volume increase of 384% over the 65-day average signals a potential trend shift.
- Total trading volume reached 1.8M shares in a single day.
- Price rose modestly by 2.37% to $4.75, but the volume surge suggests underlying strength.
- Historical data from similar cases shows a 90% success rate for positive outcomes.
- Investors may view this as a buy signal amid STTK's ongoing clinical progress.
Shattuck Labs focuses on developing bi-functional fusion proteins and targeted antibodies to address unmet needs in autoimmune and inflammatory conditions, particularly through its proprietary approach to modulating the TL1A/DR3 pathway for immune regulation. Its core pipeline includes innovative biologic therapies designed for potency, selectivity, and safety, targeting diseases like inflammatory bowel disease (IBD) and other autoimmune indications. The company's platform emphasizes Fc-silenced antibodies to enhance therapeutic efficacy while minimizing off-target effects, supported by preclinical and clinical-stage programs aimed at improving patient outcomes in chronic inflammatory disorders.
In 2025, Shattuck Labs made significant strides with new product advancements and pipeline expansions. The lead candidate, SL-325, a first-in-class DR3 blocking antibody, progressed rapidly: an Investigational New Drug (IND) application was submitted in the second quarter, leading to the initiation of a Phase 1 clinical trial in the third quarter for IBD, marking it as the first DR3 blocking antibody to enter clinical development. SL-425, an extended half-life DR3 blocking antibody, advanced to the IND-enabling stage, also targeting IBD with potential for improved dosing convenience. Additionally, the company nominated lead candidates in its bispecific DR3 blocking antibody program, currently in preclinical development for broader autoimmune indications. These developments were bolstered by a private placement financing raising up to $103 million in August 2025 to fund ongoing therapeutic antibody programs. No new services were introduced, as the focus remains on biopharmaceutical product development.
Complementing STTK's uptrend analysis are advanced tools like Tickeron's AI trading bots, which provide sophisticated insights for investors.
Tickeron's platform features AI-powered trading robots, virtual agents for stocks and ETFs, and single-ticker AI Trading Agents that are fully hedged with inverse ETFs for risk management. These bots use machine learning to deliver real-time signals, smart money management, and stock forecasts, with some achieving returns up to 158% in sectors like aerospace, mining, and ETFs. Tools such as A.I.dvisor, which analyzed STTK's volume surge, scan historical patterns to predict outcomes, offering backtested algorithms for strategies like day trading on 60-minute intervals. With no prior trading experience required, these bots alert users to buys, sells, potential profits, and stop losses, making them valuable for spotting opportunities in stocks like STTK during uptrends.
STTK's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for STTK moved out of oversold territory on June 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In of the 37 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 18, 2026. You may want to consider a long position or call options on STTK as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for STTK just turned positive on June 17, 2026. Looking at past instances where STTK's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where STTK advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
STTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for STTK entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.222) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). STTK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (454.545) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology